CpG oligodeoxynucleotides for anticancer monotherapy from preclinical stages to clinical trials
CpG oligodeoxynucleotides (CpG ODNs), the artificial versions of unmethylated CpG motifs
that were originally discovered in bacterial DNA, are demonstrated not only as potent …
that were originally discovered in bacterial DNA, are demonstrated not only as potent …
Development of CpG oligodeoxynucleotide TLR9 agonists in anti-cancer therapy
ABSTRACT Introduction Toll-like receptor-9 (TLR9) can recognize the foreign unmethylated
CpG DNA, and thus intrigue a strong Th1 response which plays a crucial role in the innate …
CpG DNA, and thus intrigue a strong Th1 response which plays a crucial role in the innate …
Polyvalent immunostimulatory nanoagents with self‐assembled CpG oligonucleotide‐conjugated gold nanoparticles
Transportvehikel: Gold‐Nanopartikel (AuNPs) werden als Träger für die nichtinvasive
Einschleusung von synthetischen Cytosinphosphatguanosin (CpG) …
Einschleusung von synthetischen Cytosinphosphatguanosin (CpG) …
Tilsotolimod with ipilimumab drives tumor responses in anti–PD-1 refractory melanoma
C Haymaker, DH Johnson, R Murthy, SE Bentebibel… - Cancer discovery, 2021 - AACR
Many patients with advanced melanoma are resistant to immune checkpoint inhibition. In the
ILLUMINATE-204 phase I/II trial, we assessed intratumoral tilsotolimod, an investigational …
ILLUMINATE-204 phase I/II trial, we assessed intratumoral tilsotolimod, an investigational …
Modulation of the tumor microenvironment by intratumoral administration of IMO-2125, a novel TLR9 agonist, for cancer immunotherapy
D Wang, W Jiang, F Zhu, X Mao… - … journal of oncology, 2018 - spandidos-publications.com
The objective of cancer immunotherapy is to prime the host's immune system to recognize
and attack malignant tumor cells. IMO‑2125, a Toll‑like receptor 9 (TLR9) agonist, exhibited …
and attack malignant tumor cells. IMO‑2125, a Toll‑like receptor 9 (TLR9) agonist, exhibited …
Interferon‑α and its effects on cancer cell apoptosis
W Shi, X Yao, Y Fu, Y Wang - Oncology Letters, 2022 - spandidos-publications.com
Interferon (IFN)‑α is a cytokine that exhibits a wide range of biological activities and is used
in various cancer treatments. It regulates numerous genes that serve roles in antiviral …
in various cancer treatments. It regulates numerous genes that serve roles in antiviral …
Toll-like receptor agonists as cancer vaccine adjuvants
D Jeon, E Hill, DG McNeel - Human Vaccines & …, 2024 - Taylor & Francis
Cancer immunotherapy has emerged as a promising strategy to treat cancer patients.
Among the wide range of immunological approaches, cancer vaccines have been …
Among the wide range of immunological approaches, cancer vaccines have been …
Minimal sequence requirements for oligodeoxyribonucleotides activating human TLR9
Abstract Synthetic oligodeoxyribonucleotides (ODNs) containing CpG (unmethylated
deoxycytidylyl-deoxyguanosine dinucleotide) motifs activate endosomal TLR9. The …
deoxycytidylyl-deoxyguanosine dinucleotide) motifs activate endosomal TLR9. The …
Species-specific minimal sequence motif for oligodeoxyribonucleotides activating mouse TLR9
Synthetic oligodeoxyribonucleotides (ODNs) containing unmethylated CpG recapitulate the
activation of TLR9 by microbial DNA. ODNs are potent stimulators of the immune response …
activation of TLR9 by microbial DNA. ODNs are potent stimulators of the immune response …
Tilsotolimod: An investigational synthetic toll-like receptor 9 (TLR9) agonist for the treatment of refractory solid tumors and melanoma
C Karime, J Wang, G Woodhead, K Mody… - Expert Opinion on …, 2022 - Taylor & Francis
Introduction Cancer immunotherapy has seen tremendous strides in the past 15 years, with
the introduction of several novel immunotherapeutic agents. Nevertheless, as clinical …
the introduction of several novel immunotherapeutic agents. Nevertheless, as clinical …